0001140361-22-010347 | 10-K | XBRL Viewer

Print Document View Excel Document

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 12,586	$ 10,604
Restricted cash	0	7,508
Accounts receivable, net of allowance for doubtful accounts of $275 and $274 at December 31, 2021 and 2020, respectively	3,433	2,944
Inventories	3,489	3,444
Prepaid expenses and other current assets	462	331
Total current assets	19,970	24,831
Property and equipment, net	6,883	5,529
Operating lease right-of-use assets	638	988
Intangible assets, net	10,083	6,345
Goodwill	8,803	8,803
Other assets	216	282
Total assets	46,593	46,778
Current liabilities:
Note payable	0	7,275
Current portion of long-term debt	0	1,478
Accounts payable	2,822	2,764
Accrued expenses and other current liabilities	6,377	4,690
Deferred revenues	3,285	2,262
Current portion of operating lease liabilities	318	369
Total current liabilities	12,802	18,838
Long-term debt, net of current portion	7,319	1,050
Deferred revenues and other liabilities	400	34
Deferred tax liability	266	254
Operating lease liability, net of current portion	392	710
Total liabilities	21,179	20,886
Commitments and contingencies (Note 12)
Stockholders' equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 34,364,679 and 33,801,045 shares issued and outstanding at December 31, 2021 and 2020, respectively	34	34
Additional paid-in capital	247,059	244,831
Accumulated deficit	(221,679)	(218,973)
Total stockholders' equity	25,414	25,892
Total liabilities and stockholders' equity	$ 46,593	$ 46,778

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 275	$ 274
Stockholders' equity:
Series C Convertible Preferred Stock, par value (in dollars per share)	$ 0.10	$ 0.10
Series C Convertible Preferred Stock, shares authorized (in shares)	10,000,000	10,000,000
Series C Convertible Preferred Stock, shares issued (in shares)	0	0
Series C Convertible Preferred Stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	150,000,000	150,000,000
Common stock shares issued on exercise of options (in shares)	34,364,679	33,801,045
Common stock, shares outstanding (in shares)	34,364,679	33,801,045

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenues, net	$ 29,977	$ 23,090
Cost of revenues	10,127	8,956
Gross profit	19,850	14,134
Operating expenses:
Engineering and product development	1,434	1,274
Selling and marketing	13,106	9,038
General and administrative	9,712	7,898
Total operating expenses	24,252	18,210
Income (loss) from operations	(4,402)	(4,076)
Other income (expense):
Interest expense	(314)	(211)
Interest income	15	150
Gain on forgiveness of debt	2,029	0
Other (expense) income, net	1,730	(61)
Loss before income tax expense	(2,672)	(4,137)
Income tax expense	(34)	(275)
Net loss	(2,706)	(4,412)
Common Shares [Member]
Other income (expense):
Net loss	$ (2,706)	$ (4,394)
Net loss per share - basic (in dollars per share)	$ (0.08)	$ (0.13)
Net loss per share - diluted (in dollars per share)	$ (0.08)	$ (0.13)
Weighted average shares outstanding - basic (in shares)	34,050,274	33,609,922
Weighted average shares outstanding - diluted (in shares)	34,050,274	33,609,922
Preferred Series C Shares [Member]
Other income (expense):
Net loss	$ 0	$ (18)
Net loss per share - basic (in dollars per share)	$ 0	$ (48.59)
Net loss per share - diluted (in dollars per share)	$ 0	$ (48.59)
Weighted average shares outstanding - basic (in shares)	0	368
Weighted average shares outstanding - diluted (in shares)	0	368

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member] Convertible Preferred Stock Series C [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Total	Convertible Preferred Stock Series C [Member]
Beginning balance at Dec. 31, 2019	$ 1	$ 33	$ 243,180	$ (214,561)	$ 28,653
Beginning balance (in shares) at Dec. 31, 2019	2,103	32,932,273
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Series C convertible preferred stock into common stock	$ (1)	$ 1	0	0	0
Conversion of Series C convertible preferred stock into common stock (in shares)	(2,103)	782,089
Stock-based compensation expense	$ 0	$ 0	1,633	0	1,633
Exercise of stock options	$ 0	$ 0	18	0	$ 18
Exercise of stock options (in shares)	0	15,000			15,000
Issuance of restricted stock	$ 0	$ 0	0	0	$ 0
Issuance of restricted stock (in shares)	0	71,683			71,683
Net loss	$ 0	$ 0	0	(4,412)	$ (4,412)	$ (18)
Ending balance at Dec. 31, 2020	$ 0	$ 34	244,831	(218,973)	25,892
Ending balance (in shares) at Dec. 31, 2020	0	33,801,045
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	$ 0	$ 0	1,643	0	1,643
Exercise of stock options	$ 0	$ 0	0	0	$ 0
Exercise of stock options (in shares)	0	329,076			329,076
Issuance of restricted stock	$ 0	$ 0	0	0	$ 0
Issuance of restricted stock (in shares)	0	234,558			234,558
Issuance of common stock warrants in connection with Senior Term Facility	$ 0	$ 0	585	0	$ 585
Net loss	0	0	0	(2,706)	(2,706)	$ 0
Ending balance at Dec. 31, 2021	$ 0	$ 34	$ 247,059	$ (221,679)	$ 25,414
Ending balance (in shares) at Dec. 31, 2021	0	34,364,679

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (2,706)	$ (4,412)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	3,736	3,585
Amortization of right-of-use asset	350	326
Amortization of deferred financing costs and debt discount	37	0
Provision for doubtful accounts	1	90
Stock-based compensation	1,643	1,633
Loss on disposal of property and equipment	140	24
Gain on forgiveness of debt	(2,029)	0
Deferred taxes	12	254
Changes in operating assets and liabilities:
Accounts receivable	(490)	1,352
Inventories	(45)	(417)
Prepaid expenses and other assets	(65)	247
Accounts payable	58	884
Accrued expenses and other liabilities	1,679	(588)
Deferred revenues	(444)	(570)
Operating lease liabilities	(369)	(312)
Net cash provided by operating activities	1,508	2,096
Cash flows from investing activities:
Cash paid in connection with asset acquisition	(3,473)	0
Purchase of property and equipment	(3,653)	(2,159)
Net cash used in investing activities	(7,126)	(2,159)
Cash flows from financing activities:
Proceeds from exercise of stock options	0	18
Proceeds from long-term debt	8,000	2,528
Payment of deferred financing costs	(133)	0
Repayment of note payable	(7,275)	0
Repayments of long-term debt	(500)	0
Net cash provided by financing activities	92	2,546
Net (decrease) increase in cash, cash equivalents and restricted cash	(5,526)	2,483
Cash, cash equivalents and restricted cash at beginning of year	18,112	15,629
Cash, cash equivalents and restricted cash at end of year	12,586	18,112
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	222	211
Supplemental schedule of non-cash investing and financing activities:
Issuance of common stock warrants in connection with Senior Term Facility	585	0
Assumed deferred revenues in connection with asset acquisition	$ 1,841	$ 0

Organization and Nature of Business	12 Months Ended
Organization and Nature of Business	Dec. 31, 2021
Organization and Nature of Business [Abstract]
Organization and Nature of Business	STRATA Skin Sciences, Inc. and Subsidiary Notes to Consolidated Financial Statements 1. Organization and Nature of Business STRATA Skin Sciences, Inc. (the “Company”) is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. In January 2022, the Company acquired the TheraClear acne treatment device to broaden its opportunities with expansion potential into the acne care market. COVID-19 Pandemic In late 2019, there was an outbreak of a new strain of coronavirus (“COVID-19”) which became a global pandemic. The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains, constrained work force participation and created significant volatility and disruption of financial markets. In addition, the pandemic led to the suspension of elective procedures in the U.S. and to the temporary closure of many physician practices which are the Company’s primary customers. While most offices reopened, some physician practices closed and never reopened, and the ongoing impact of the COVID-19 pandemic and its variants on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frames will depend on future developments, including the duration and ongoing spread of the COVID-19 outbreak and its variants, continued or renewed restrictions on business operations and transport, any governmental and societal responses thereto, including legislative or regulatory changes as well as the percentage of the populace vaccinated and the effectiveness of COVID-19 vaccines and the continued impact on worldwide economic and geopolitical conditions, all of which are uncertain and cannot be predicted. Domestically, as the procedures for which the Company’s devices are used are elective in nature; and as social distancing, travel restrictions, quarantines and other restrictions became prevalent in the United States, this had a negative impact on the Company’s recurring revenue model and its financial position and cash flow. The virus has disrupted the supply chains world-wide which the Company depends upon to provide a steady source of components to manufacture and repair the Company’s devices. To mitigate the impact of COVID-19 the Company took a variety of measures to ensure the availability and functioning of its critical infrastructure by implementing business continuity plans. To promote the safety and security of its employees, while complying with various government mandates including work-from-home arrangements and social-distancing initiatives to reduce the transmission of COVID-19, the Company is complying with federal and local regulations at its facilities. In addition, the Company created and executed programs utilizing its direct to consumer advertising and call center to contact patients and partner clinics to restart the Company’s partners’ businesses. In October 2021, the Company implemented a policy whereby all Company employees are required to be vaccinated or complete weekly COVID-19 testing. To conserve its cash in order to mitigate the ongoing impact of the COVID-19 pandemic, in the second quarter of 2020 the Company furloughed employees, who returned to work after the Company received proceeds from the Paycheck Protection Program (“PPP”) (Note 11). The Company also reduced discretionary spending in 2020. Supply chain disruptions which began during the pandemic have continued and may continue for the foreseeable future. While the Company’s operations have not been materially impacted by the general trends in supply chain problems, the Company continues to monitor and assess potential risks. Liquidity and Going Concern The Company has been negatively impacted by the ongoing COVID-19 pandemic, has historically experienced recurring losses, has been dependent on raising capital from the sale of securities in order to continue to operate and refinanced its debt at a lower interest rate. During the COVID-19 pandemic, the Company received cash proceeds from the PPP Loan, which was forgiven, and the Economic Injury Disaster Loan (the “EIDL Loan”) that was repaid at the time the Senior Term Facility was entered into with MidCap Financial Trust in September 2021 (Note 11). Additionally, in October 2021, the Company entered into an equity distribution agreement with an investment bank under which the Company may sell up to $11.0 million of its common stock in registered “at-the-market” offerings (Note 13). Management believes that the Company’s cash and cash equivalents, combined with the anticipated revenues from the sale or use of its products, will be sufficient to satisfy the Company’s working capital needs, capital asset purchases, outstanding commitments and other liquidity requirements associated with its existing operations for at least the next 12 months following the date of the issuance of these consolidated financial statements. However, the negative impact of the ongoing COVID-19 outbreak on the financial markets and supply chain disruptions could interfere with the Company’s ability to access financing or financing on favorable terms.

Basis of Presentation and Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Summary of Significant Accounting Policies

2. Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements are presented in U.S. dollars and have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Updates (“ASUs”) of the Financial Accounting Standards Board (“FASB”). The accompanying consolidated financial statements include the accounts of the Company and Photomedex India Private Limited, its wholly-owned subsidiary in India. No operating activities have occurred within the Company’s subsidiary as of and during the years ended December 31, 2021 and 2020.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments involve revenue recognition with respect to deferred revenues and the contract term and valuation allowances of accounts receivable, inputs used when evaluating goodwill for impairment, inputs used in the valuation of acquired intangible assets, state sales and use tax accruals, the estimated useful lives of intangible assets, and the valuation allowance related to deferred tax assets. Actual results could differ from those estimates.

Reclassifications

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation.

Concentrations of Credit Risk and Major Customers

The Company’s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage limit of $0.3 million per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little credit risk to the Company.

Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers.

The Company had one customer, an international distributor from which it earns dermatology recurring procedures and dermatology procedures equipment revenues, that accounted for more than 10% of the Company’s revenues for the year ended December 31, 2021, and its former international master distributor from which it earned dermatology procedures equipment revenues that accounted for more than 10% of the Company’s revenues for the year ended December 31, 2020. Revenues from this customer and the former international master distributor were $3.4 million and $2.7 million, or 11% and 12%, of total net revenues during the years ended December 31, 2021 and 2020, respectively. Accounts receivable associated with the Company’s customer and former international master distributor were less than 10% of total accounts receivable as of December 31, 2021 and 2020, respectively. No other customer represented more than 10% of total accounts receivable as of December 31, 2021 or 2020.

Cash and Cash Equivalents

The Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2021 and 2020, cash equivalents consisted of credit card transactions with settlement terms of less than five days.

Restricted Cash

Restricted cash represents amounts held on deposit at a commercial bank used to secure the Company’s Note Payable. The Note Payable was repaid during the year ended December 31, 2021. The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2021		2020
Cash and cash equivalents	$	12,586	$	10,604
Restricted cash		—		7,508
Total cash and restricted cash presented in the consolidated statements of cash flows	$	12,586	$	18,112

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable primarily relates to amounts due from customers, which are typically due within 30 to 90 days from invoice date. The Company provides credit to its customers in the normal course of business and maintains allowances for potential credit losses. The Company does not require collateral or other security for accounts receivable. The Company maintains allowances for doubtful accounts for estimated losses resulting from amounts deemed to be uncollectible from its customers. These allowances are for specific amounts on certain customer accounts based on facts and circumstances determined on a case-by-case basis. The Company writes off accounts receivable when they are considered uncollectible, and payments subsequently received on such receivables are credited to bad debt expense. The Company does not recognize interest accruing on accounts receivable past due.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is determined based on purchased cost for raw materials and all production cost related to the laser manufacturing process (labor and indirect manufacturing cost, including sub-contracted work components) for work-in-process and finished goods is classified as inventory. For the Company’s products, cost is determined on the first-in, first-out method. Work-in-process is immaterial, given the typically short manufacturing cycle and therefore, is disclosed in conjunction with raw materials.

The Company’s equipment for the treatment of skin disorders (e.g. the XTRAC) will either (i) be placed in a physician’s office and remain the property of the Company (at which date such equipment is transferred to property and equipment) or (ii) be sold to distributors or physicians directly. The cost to build a laser, whether for sale or for placement, is accumulated in inventory.

Reserves for slow-moving and obsolete inventories are provided based on historical experience and product demand. Management evaluates the adequacy of these reserves periodically based on forecasted sales and market trends.

Property and Equipment

Property and equipment are recorded at cost less accumulated depreciation. Maintenance and repairs are charged to expense as incurred and costs of improvements and renewals are capitalized. Upon retirement or disposition, the applicable property and equipment amounts are deducted from the accounts and any gain or loss is recorded in the consolidated statements of operations. Depreciation and amortization are recognized using the straight-line method based on the estimated useful lives of the related assets. The Company uses an estimated useful life of three years for computers, hardware and software, five years for machinery and equipment and seven years for furniture and fixtures and the lesser of the useful life or lease term for leasehold improvements.

Intangible Assets

Intangible assets consist of core technology, product technology, customer relationships, trademarks and distribution rights. Intangible assets are amortized over the period of estimated benefit using the straight-line method and estimated useful lives ranging from three to 12 years.

Goodwill

Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is not amortized, but is subject to an annual impairment test. The Company has two reporting units and goodwill is allocated to the reporting units.

The Company performs its goodwill impairment test on an annual basis in the fourth quarter of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit’s goodwill is less than the carrying value of the reporting unit’s goodwill. The Company bypassed the qualitative assessment and did a quantitative assessment by comparing the fair value of a reporting unit with its carrying amount.The Company’s annual goodwill impairment test resulted in no impairment charges during the years ended December 31, 2021 and 2020.

Impairment of Long-Lived Assets and Intangibles

The Company reviews its long-lived assets and intangible assets subject to amortization for impairment whenever events or changes in circumstances indicate the carrying amount of an asset group may not be recoverable. Recoverability of assets held and used is measured by comparison of the carrying amount of an asset group to future net cash flows expected to be generated by the asset group. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group, less costs to sell. The Company did not record any charges related to asset impairment during the years ended December 31, 2021 and 2020.

Fair Value Measurements

The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires the use of observable inputs and minimizes the use of unobservable inputs. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

•	Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

The Company offers a standard warranty on product sales generally for a one to two-year period, however, the Company has offered longer warranty periods, ranging from three to four years, in order to meet competition or to meet customer demands. The Company provides for the estimated cost of the future warranty claims on the date the product is sold. The activity in the warranty accrual during the years ended December 31, 2021 and 2020 is summarized as follows (in thousands):

	December 31,
	2021			2020
Balance, beginning of year	$	113		$	232
Additions		71			67
Expirations and claims satisfied		(105	)		(186	)
Total		79			113
Less current portion within accrued expenses and other current liabilities		(59	)		(87	)
Balance within deferred revenues and other liabilities	$	20		$	26

Debt Issuance Costs

The Company capitalizes direct costs incurred to obtain debt financing and amortizes these costs to interest expense over the term of the debt using the effective interest method. These costs are recorded as a debt discount and are netted against the related debt on the Company’s consolidated balance sheets.

Revenue Recognition

Revenues from the Company’s dermatology recurring procedures customers are earned by providing physicians with its laser products and charging the physicians a fee for a fixed number of treatment sessions or a fixed fee for a specified period of time not to exceed an agreed upon number of treatments; if that number is exceeded additional fees will have to be paid. The placement of the laser products at physician locations represents embedded leases which are accounted for as operating leases. For the lasers placed-in service under these arrangements, the terms of the domestic arrangements are generally 36 months with automatic one-year renewals and include a termination clause that can be effected at any time by either party with 30 to 60 day notice. Amounts paid are generally non-refundable. Sales of access codes for a fixed number of treatment sessions are considered variable treatment code payments and are recognized as revenue over the estimated usage period of the agreed upon number of treatments. Sales of access codes for a specified period of time are recognized as revenue on a straight-line basis as the lasers are being used over the term period specified in the agreement. Variable treatment code payments that will be paid only if the customer exceeds the agreed upon number of treatments are recognized only when such treatments are being exceeded and used. Internationally, the Company generally sells access codes for a fixed amount on a monthly basis to its distributors and the terms are generally 48 months, with termination in the event of the customers’ failure to remit payments timely, and include a potential buy-out at the end of the term of the contract. Currently, this is the only foreign recurring revenue. Prepaid amounts recorded in deferred revenue and customer deposits recorded in accounts payable are recognized as revenue over the lease term in the patterns described above. Pricing is fixed with the customer. With respect to lease and non-lease components, the Company adopted the practical expedient to account for the arrangement as a single lease component.

Revenues from the Company’s dermatology procedures equipment are recognized when control of the promised goods or services is transferred to its customers or distributors, in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. Accordingly, the Company determines revenue recognition through the following steps:

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

Accounting for the Company’s contracts involves the use of significant judgments and estimates including determining the separate performance obligations, allocating the transaction price to the different performance obligations and determining the method to measure the entity’s performance toward satisfaction of performance obligations that most faithfully depicts when control is transferred to the customer. The Company allocates the contract’s transaction price to each performance obligation using the Company’s best estimate of the standalone selling price for each distinct good or service in the contract. The Company maximizes the use of observable inputs by beginning with average historical contractual selling prices and adjusting as necessary and on a consistent and rational basis for other inputs such as pricing trends, customer types, volumes and changing cost and margins.

Revenues from dermatology procedures equipment are recognized when control of the promised products is transferred to either the Company’s distributors or end-user customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products (the transaction price). Control transfers to the customer at a point in time. To indicate the transfer of control, the Company must have a present right to payment and legal title must have passed to the customer. The Company ships most of its products FOB shipping point, and as such, the Company primarily transfers control and records revenue upon shipment. From time to time the Company will grant certain customers, for example governmental customers, FOB destination terms, and the transfer of control for revenue recognition occurs upon receipt. The Company has elected to recognize the cost of freight and shipping activities as fulfillment costs. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of the underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenues.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2021		2020
Dermatology recurring procedures	$	22,528	$	17,409
Dermatology procedures equipment		7,449		5,681
Total net revenues	$	29,977	$	23,090

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from dermatology recurring procedures (in thousands):

Years ending December 31:
2022	$	1,680
2023		1,624
2024		1,303
2025		530
2026		4
	$	5,141

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year, which are fully or partially unsatisfied at the end of the period. Remaining performance obligations include the potential obligation to perform under extended warranties but exclude any dermatology procedures equipment accounted for as leases. As of December 31, 2021 and 2020, the aggregate amount of the transaction price allocated to remaining performance obligations was $26 thousand and $115 thousand, respectively, and the Company expects to recognize $12 thousand and $108 thousand, respectively, of the remaining performance obligations within one year and the remainder over one to three years. Contract assets primarily relate to the Company’s rights to consideration for work completed in relation to its services performed but not billed at the reporting date. The contract assets are transferred to receivables when the rights become unconditional. Currently, the Company does not have any contract assets which have not transferred to a receivable.

Contract liabilities primarily relate to extended warranties where the Company has received payments but has not yet satisfied the related performance obligations. The allocations of the transaction price are based on the price of stand-alone warranty contracts sold in the ordinary course of business. The advance consideration received from customers for the warranty services is a contract liability that is recognized ratably over the warranty period. As of December 31, 2021 and 2020, the $12 thousand and $108 thousand of short-term contract liabilities, respectively, is presented as deferred revenues and the $14 thousand and $7 thousand of long-term contract liabilities, respectively, is presented within deferred revenues and other liabilities on the consolidated balance sheets, respectively. For the years ended December 31, 2021 and 2020, the Company recognized $0.1 million and $0.2 million, respectively, as revenue from amounts classified as contract liabilities (i.e. deferred revenues) as of December 31, 2020 and 2019.

With respect to contract acquisition costs, the Company applied the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Advertising costs are expensed as incurred and included in selling and marketing expenses within the Company’s consolidated statement of operations. The Company recognized advertising costs of $1.6 million and $0.7 million during the years ended December 31, 2021 and 2020, respectively.

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Estimating the fair value of share-based awards requires the input of subjective assumptions, including the expected life of the options and stock price volatility. The Company accounts for forfeitures of stock option awards as they occur. The estimated fair value of restricted stock awards is equal to the Company’s common stock price at the grant date. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in estimating the fair value of stock-option awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Income Taxes

The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities, as well as on net operating loss carryforwards, and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is not more likely than not that all or some portion of the deferred tax asset will be realized.

The Company recognizes the tax effects of uncertain tax positions only if the position is “more-likely-than-not” to be sustained were it to be challenged by a taxing authority. The assessment of the tax position is based solely on the technical merits of the position, without regard to the likelihood that the tax position may be challenged. If an uncertain tax position meets the “more-likely-than-not” threshold, the largest amount of tax benefit that is more than 50% likely to be recognized upon ultimate settlement with the taxing authority is recorded. The Company has no uncertain tax positions as of December 31, 2021. The Company includes interest and penalties related to income tax obligations within income tax expense. The Company’s tax years are still under open status from 2017 to present.

Net Loss Per Share

Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities such as unvested restricted stock awards, stock options and warrants for common stock which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same as for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.

Shares of the Company’s Series C convertible preferred stock are subordinate to all other securities at the same subordination level as common stock and they participate in all dividends and distributions declared or paid with respect to common stock of the Company, on an as-converted basis. Therefore, the Series C convertible preferred stock meets the definition of common stock. Net loss per share is presented for each class of security meeting the definition of common stock. The net loss is allocated to each class of security meeting the definition of common stock based on their contractual terms.

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2021		2020
Unvested restricted stock units		90,540		—
Stock options		3,938,613		5,292,888
Common stock warrants		373,626		19,812
		4,402,779		5,312,700

Recent Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, as amended subsequently by ASUs 2018-19, 2019-04, 2019-05, 2019-10, 2019-11 and 2020-03. The guidance in the ASUs requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used. The standard also establishes additional disclosures related to credit risks. This standard is effective for fiscal years beginning after December 15, 2022 and early adoption is permitted. The Company does not believe this will have a material effect on its consolidated financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. ASU 2019-12 eliminated certain exceptions and changed guidance on other matters. The exceptions relate to the allocation of income taxes in separate company financial statements, tax accounting for equity method investments and accounting for income taxes when the interim period year-to-date loss exceeds the anticipated full year loss. The changes relate to the accounting for franchise taxes that are income-based and non-income-based, determining if a step up in tax basis is part of a business combination or if it is a separate transaction, when enacted tax law changes should be included in the annual effective tax rate computation, and the allocation of taxes in separate company financial statements to a legal entity that is not subject to income tax. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019-12 on January 1, 2021 did not have a material effect on the Company’s consolidated financial statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and in January 2021, the FASB issued ASU 2021-01, Reference Rate Reform (Topic 848): Scope. These pronouncements provide temporary optional expedients and exceptions for applying GAAP principles to contract modifications and hedging relationships to ease the financial reporting burdens of the expected market transition from LIBOR and other interbank offered rates to alternative reference rates. The transition period for adopting these ASUs is March 2020 through December 31, 2022. The Company continues to evaluate the temporary expedients and options available under this guidance and the effects of these pronouncements and, as the Company does not have any hedging activities, does not believe this will have a material effect on its consolidated financial statements.

In August 2020, the FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s own Equity. The pronouncement simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. Specifically, the ASU simplifies accounting for convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for it and simplifies the diluted earnings per share (EPS) calculations in certain areas. The guidance is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted. The Company does not currently engage in contracts covered by this guidance and does not believe it will have a material effect on the Company’s consolidated financial statements, but it could in the future.

In May 2021, the FASB issued ASU 2021-04, Earnings per Share (Topic 260), Debt – Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges or Freestanding Equity-Classified Written Call Options. The pronouncement outlines how an entity should account for modifications made to equity-classified written call options, including stock options and warrants to purchase the entity’s own common stock. The guidance in the ASU requires an entity to treat a modification of an equity-classified written call option that does not cause the option to become liability-classified as an exchange of the original option for a new option. This guidance applies whether the modification is structured as an amendment to the terms and conditions of the equity-classified written call option or as termination of the original option and issuance of a new option. The guidance is effective prospectively for fiscal years beginning after December 15, 2021 and early adoption is permitted. The adoption of this guidance on January 1, 2022 did not have a material effect on the consolidated financial statements.

Pharos Asset Acquisition

12 Months Ended

Dec. 31, 2021

Pharos Asset Acquisition [Abstract]

Pharos Asset Acquisition

3. Pharos Asset Acquisition

In August 2021, the Company acquired certain assets and liabilities related to the U.S. dermatology Pharos business from Ra Medical Systems, Inc. (“Ra Medical”). Ra Medical’s Pharos excimer laser system holds FDA clearance to treat chronic skin diseases, including psoriasis, vitiligo, atopic dermatitis and leukoderma. The acquisition of these assets and liabilities allows the Company to market its full business solutions to Ra Medical’s existing customer base comprised of 400 dermatology practices offering opportunities to increase its recurring revenue base and a pathway to gain additional placements for the Company’s XTRAC excimer laser system.

The purchase price of $3.7 million was paid in cash at the time of acquisition. In addition, the Company assumed certain extended warranty service contracts associated with acquired laser system products. Concurrent with the purchase of the net assets, the Company and Ra Medical entered into a services agreement whereby Ra Medical will provide certain transitional services for the Company as it integrates the acquired assets into the Company. The Company determined this transaction represented an asset acquisition as substantially all of the value was in the acquired customer list intangible asset as defined by ASC 805, Business Combinations (“ASC 805”).

The purchase price was allocated, on a relative fair value basis, to the acquired inventory, customer lists and deferred revenues as follows (in thousands):

Consideration:
Cash payment	$	3,700
Transaction costs		57
Total consideration	$	3,757
Assets acquired:
Inventory	$	284
Customer lists		5,314
Total assets acquired	$	5,598
Liabilities assumed:
Deferred revenues – service contracts	$	1,841
Total liabilities assumed	$	1,841

Net assets acquired

3,757

The customer lists intangible asset is being amortized on a straight-line basis over a period of 12 years. As the transaction was accounted for as an asset acquisition, the Company allocated consideration paid to the inventory acquired and the deferred revenues assumed, with the remaining consideration paid allocated to the customer lists intangible asset, which also equals its estimated fair value. The intangible asset was valued using an excess earnings model. Significant assumptions used in the excess earnings model include estimated customer sales growth, customer attrition and weighted average cost of capital of 3%, 5% and 17%, respectively.

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2021
Fair Value Measurements [Abstract]
Fair Value Measurements	4. Fair Value Measurements The carrying values of cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, and accounts payable on the Company’s consolidated balance sheets approximated their fair values as of December 31, 2021 and 2020 due to their short-term nature. The carrying value of the Company’s current Senior Term Facility approximated its fair value as of December 31, 2021 due to its variable interest rate.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2021

Inventories [Abstract]

Inventories

5. Inventories

Inventories consist of the following (in thousands):

	December 31,
	2021		2020
Raw materials and work-in-process	$	3,201	$	2,949
Finished goods		288		495
	$	3,489	$	3,444

Work-in-process is immaterial given the Company’s typically short manufacturing cycle and therefore, is included in with raw materials.

Property and Equipment

12 Months Ended

Dec. 31, 2021

Property and Equipment [Abstract]

Property and Equipment

6. Property and Equipment

Property and equipment consist of the following (in thousands):

	December 31,
	2021			2020
Lasers placed-in-service	$	25,949		$	22,942
Equipment, computer hardware and software		238			146
Furniture and fixtures		213			243
Leasehold improvements		254			43
		26,654			23,374
Less: accumulated depreciation and amortization		(19,771	)		(17,845	)
	$	6,883		$	5,529

The Company recorded depreciation and amortization expense of $2.1 million and $2.0 million during the years ended December 31, 2021 and 2020, respectively.

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Leases

7. Leases

The Company recognizes right-of-use assets (“ROU assets”) and operating lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than 12 months. The Company adopted the short-term accounting election for leases with a duration of less than one year. The Company leases its facilities and certain IT and office equipment under non-cancellable operating leases. All of the Company’s leasing arrangements are classified as operating leases with remaining lease terms ranging from 1 to 3 years, and one facility lease has a renewal option for two years. Renewal options have been excluded from the determination of the lease term as they are not reasonably certain of exercise.

Operating lease costs were $0.4 million for each of the years ended December 31, 2021 and 2020. Cash paid for amounts included in the measurement of operating lease liabilities was $0.5 million and $0.4 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, the incremental borrowing rate was 9.76% and the weighted average remaining lease term was 2.3 years and 3.1 years, respectively.

The following table summarizes the Company’s operating lease maturities as of December 31, 2021 (in thousands):

Years ending December 31:
2022	$	371
2023		242
2024		186
Total remaining lease payments		799
Less: imputed interest		(89	)
Total lease liabilities	$	710

With respect to lease and non-lease components, the Company adopted the practical expedient to account for the lessee arrangement as a single lease component.

Intangible Assets and Goodwill

12 Months Ended

Dec. 31, 2021

Intangible Assets and Goodwill [Abstract]

Intangible Assets and Goodwill

8. Intangible Assets and Goodwill

Intangible assets consist of the following (in thousands):

December 31, 2021	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(3,705	)	$	1,995
Product technology		2,000		(2,000	)		—
Customer relationships		6,900		(4,485	)		2,415
Tradenames		1,500		(975	)		525
Pharos customer lists		5,314		(166	)		5,148
	$	21,414	$	(11,331	)	$	10,083

December 31, 2020	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(3,135	)	$	2,565
Product technology		2,000		(2,000	)		—
Customer relationships		6,900		(3,795	)		3,105
Tradenames		1,500		(825	)		675
	$	16,100	$	(9,755	)	$	6,345

The Company recorded amortization expense of $1.6 million during each of the years ended December 31, 2021 and 2020.

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2022	$	1,853
2023		1,853
2024		1,853
2025		1,148
2026		443

Goodwill consists of the following (in thousands):

	December 31,
	2021		2020
Dermatology recurring procedures segment	$	7,958	$	7,958
Dermatology procedures equipment segment		845		845
	$	8,803	$	8,803

Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2021

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

9. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2021		2020
Warranty obligations	$	59	$	87
Compensation and related benefits		2,052		891
State sales, use and other taxes		3,697		3,105
Professional fees and other		569		607
	$	6,377	$	4,690

Note Payable	12 Months Ended
Note Payable	Dec. 31, 2021
Note Payable [Abstract]
Note Payable	10. Note Payable In December 2020, the Company had renewed its $7.3 million loan with a commercial bank pursuant to a one-year Fixed Rate – Term Promissory Note (the “Note”). The Company’s obligations under the Note were secured by an Assignment and Pledge of Time Deposit (“Time Deposit”), under which the Company had pledged to the commercial bank the proceeds of a time deposit account in the amount of the loan and recorded the time deposit and accrued interest as restricted cash on the balance sheet. The principal was due on December 30, 2021 with no penalties for prepayments. The interest rate was fixed at 1.40%. The secured time deposit had a fixed interest rate of 0.40%. The Company repaid the Note with the proceeds from the Time Deposit in September 2021.

Long-term Debt

12 Months Ended

Dec. 31, 2021

Long-term Debt [Abstract]

Long-term Debt

11. Long-Term Debt

Senior Term Facility

On September 30, 2021, the Company entered into a credit and security agreement with MidCap Financial Trust, also acting as the administrative agent, and the lenders identified therein (“Senior Term Facility”). The Senior Term Facility provides for an $8.0 million senior term loan that was drawn upon by the Company upon executing the agreement. On September 30, 2021, the Company also repaid the outstanding principal and interest for its Note (Note 10) and the Economic Injury Disaster Loan. Borrowings under the Senior Term Facility bear interest at LIBOR (with a LIBOR floor rate of 0.50%) plus 7.50% per year and mature on September 1, 2026, unless terminated earlier. The interest rate was 8.00% as of December 31, 2021. The Company is obligated to make monthly interest-only payments through September 30, 2024. From October 1, 2024 to the date of maturity, the Company will make 24 equal monthly principal payments plus interest, and all borrowings are secured by substantially all of the Company’s assets. The Senior Debt Facility was amended on January 10, 2022 to provide MidCap Financial Trust’s consent to the acquisition of TheraClear (Note 18).

The Company may voluntarily prepay the outstanding term loan, with such prepayment of at least $5.0 million, at any time upon 30 days’ written notice. Upon prepayment, the Company will be required to pay a prepayment fee equal to (i) 4.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made within 12 months of September 30, 2021, (ii) 3.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 12 months and 24 months after September 30, 2021, (iii) 2.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made between 24 months and 36 months after September 30, 2021, or (iv) 1.00% of the outstanding principal prepaid or required to be prepaid (whichever is greater), if the prepayment is made after 36 months after September 30, 2021 and prior to the maturity date.

The Senior Term Facility contains certain customary representations and warranties, affirmative covenants and conditions. The Senior Term Facility also contains a number of negative covenants that subject the Company to certain exceptions and waivers and restrictions, as defined in the agreement. In addition, the Senior Term Facility contains a quarterly financial covenant that requires the Company to not have less than $24.0 million of net revenue for the trailing 12-month period, with compliance measured on the last day of each fiscal quarter beginning on September 30, 2021. At December 31, 2021, the minimum net revenue threshold was $25.0 million. The minimum net revenue threshold will increase to $30.0 million by December 31, 2023. At December 31, 2021, the Company was in compliance with all financial and nonfinancial covenants within the Senior Term Facility.

The Senior Term Facility contains customary indemnification obligations and customary events of default, including, among other things, (i) nonpayment, (ii) breach of warranty, (iii) nonperformance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) regulatory matters, (x) failure to remain a publicly traded company, and (xi) material adverse event. Where an event of default arises from certain bankruptcy events, the commitments shall automatically and immediately terminate and the principal of, and interest then outstanding on, all of the loans shall become immediately due and payable. Subject to certain notice requirements and other conditions, upon the occurrence of other events of default, including the occurrence of a condition having or reasonably likely to have a material adverse effect, commitments may be terminated and the principal of, and interest then outstanding on, all of the loans may become immediately due and payable. At December 31, 2021, no event of default had occurred and the Company believed that events or conditions having a material adverse effect, giving rise to an acceleration of any amounts outstanding under the Senior Term Facility, had not occurred and was remote.

In connection with entering into the Senior Term Facility, the Company issued an affiliate of the lender a warrant to purchase 373,626 shares of the Company’s common stock at an initial exercise price of $1.82 per share. The warrant is equity classified and is exercisable at any time on or prior to the tenth anniversary of its issue date. The estimated fair value of the warrants was $0.6 million and determined using the Black-Scholes option pricing model. The key assumptions used in the Black-Scholes option pricing model were (i) an expected term of ten years, (ii) expected volatility of 88.6%, (iii) a risk-free rate of 1.50% and (iv) no estimated dividend yield. In addition, the Company incurred third party costs and lender fees of $0.1 million. The proceeds were allocated on a basis that approximates the relative fair value method. The fair value of the warrants and fees incurred were recorded as a debt discount and are being recognized as interest expense over the life of the Senior Term Facility using the effective-interest method. The unamortized debt discount was $0.7 million as of December 31, 2021. The Company recognized interest expense of $0.3 million during the year ended December 31, 2021, of which $37 thousand was related to the amortization of the debt discount.

Future minimum principal payments at December 31, 2021 are as follows (in thousands):

Years ending December 31:
2024	$	1,000
2025		4,000
2026		3,000
	$	8,000

Paycheck Protection Program Loan

On April 22, 2020, the Company closed a loan of $2.0 million (the “PPP Loan”) from a commercial bank, pursuant to the Paycheck Protection Program (“PPP”) administered by the Small Business Administration (the “SBA”) pursuant to the CARES Act. The PPP Loan would have matured on May 1, 2022 and bore an interest rate of 1% per year. Payments of principal and interest of any unforgiven balance was scheduled to commence December 1, 2020, but was deferred until the SBA approved of the forgiveness amount. In the second quarter of 2021, the Company received notification that the PPP Loan had been forgiven. Accordingly, the Company recorded a gain on forgiveness of debt in the amount of the loan of $2.0 million.

Economic Injury Disaster Loan

On May 22, 2020, the Company secured the EIDL Loan from the SBA under its Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business. The principal amount of the EIDL Loan is up to $0.5 million, with proceeds to be used for working capital purposes, and is collateralized by all the Company’s assets. On June 12, 2020, the Company received these funds from the SBA. Interest accrued at the rate of 3.75% per year. Installment payments, including principal and interest, were originally due monthly beginning March 26, 2021 (12 months from the date of the promissory note) in the amount of $2 thousand. In March 2021, the SBA deferred payments on the EIDL loans by an additional 12 months. The balance of principal and interest was payable over the next 30 years from the date of the promissory note. There were no penalties for prepayment. Based upon guidance issued by the SBA on June 19, 2020, the EIDL Loan was not required to be refinanced by the PPP Loan. On September 30, 2021, the Company repaid this loan in full.

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2021
Commitments and Contingencies [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Legal Matters In the ordinary course of business, the Company is routinely a defendant in or party to pending and threatened legal actions and proceedings, including actions brought on behalf of various classes of claimants. These actions and proceedings are generally based on alleged violations of employment, contract and other laws. In some of these actions and proceedings, claims for substantial monetary damages are asserted against the Company. In the ordinary course of business, the Company is also subject to regulatory and governmental examinations, information gathering requests, inquiries, investigations, and threatened legal actions and proceedings. In connection with formal and informal inquiries by federal, state, local and foreign agencies, the Company receives numerous requests, subpoenas and orders for documents, testimony and information in connection with various aspects of its activities. Sales and Use Tax Matters The Company records state sales tax collected and remitted for its customers on dermatology procedures equipment sales on a net basis, excluded from revenue. The Company’s sales tax expense that is not presently being collected and remitted for the recurring revenue business is recorded in general and administrative expenses within the consolidated statements of operations. The Company believes its state sales and use tax accruals have been properly recognized such that, if the Company’s arrangements with customers are deemed more likely than not that the Company would not be exempt from sales tax in a particular state, the basis for measurement of the state sales and use tax is calculated in accordance with ASC 405, Liabilities, as a transaction tax. If and when the Company is successful in defending itself or in settling the sales tax obligation for a lesser amount, the reversal of this liability is to be recorded in the period the settlement is reached. However, the precise scope, timing and time period at issue, as well as the final outcome of any audit and actual settlement, remains uncertain. In the ordinary course of business, the Company is, from time to time, subject to audits performed by state taxing authorities. These actions and proceedings are generally based on the position that the arrangements entered into by the Company are subject to sales and use tax rather than exempt from tax under applicable law. Several states have assessed the Company an aggregate of $2.4 million including penalties and interest for the period from March 2014 through April 2020. The Company received notification that an administrative state judge issued an opinion finding in favor of the Company that the sale of XTRAC treatment codes was not taxable as sales tax with respect to that state’s first assessment. This ruling covers $1.5 million of the total $2.4 million of assessments. The jurisdiction filed an appeal of the administrative law judge’s finding and, following the submission of legal briefs by both sides and oral argument held in January 2022, the appeal is still in process. The Company is also in another jurisdiction’s administrative process of appeal with respect to the remaining $0.9 million of assessments, and the timing of the process has been impacted by the COVID-19 pandemic. If there is a determination that the true object of the Company’s recurring revenue model is not exempt from sales taxes and is not a prescription medicine, or the Company does not have other defenses where the Company prevails, the Company may be subject to sales taxes in those particular states for previous years and in the future, plus potential interest and penalties. Employee 401(k) Savings Plan The Company sponsors a 401(k) defined contribution retirement savings plan that covers all eligible employees who have met the minimum age and service requirements. Under the plan, eligible employees may contribute a portion of their annual compensation into the plan up to IRS annual limits. The Company has elected to make matching contributions to the plan based on percentage of the employee’s contribution. For the years ended December 31, 2021 and 2020, the Company’s contributions to the plan were $0.3 million and $0.2 million, respectively. Contingent Shares In the event of certain contingencies, the investors in the equity financing in May 2018 may receive additional shares issued pursuant to the Retained Risk Provisions as defined in the Stock Purchase Agreements (“SPAs”). There were additional contingencies included in the SPAs that expired in May 2020 did not result in the issuance of shares.

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2021
Stockholders' Equity [Abstract]
Stockholders' Equity	13. Stockholders’ Equity Preferred Stock The Company is authorized to issue preferred stock with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors. Other than the limitations on conversions to keep each such holder’s beneficial ownership below 9.99%, the terms of the Series C convertible preferred stock generally bestow the same rights to each holder as such holder would receive if they were common stock shareholders and are not redeemable by the holders, except that the Series C convertible preferred stock shares do not have voting rights. Each share of Series C convertible preferred stock has a stated value of $1,000 and is convertible into shares of common stock at a conversion price equal to $2.69. During the year ended December 31, 2020, the Series C convertible preferred investors converted 2,103 shares of Series C preferred stock into 782,089 shares common stock. No preferred shares were outstanding as of December 31, 2021 and 2020. Common Stock The Company issued 329,076 shares and 15,000 shares upon the exercise of options and issued 234,558 shares and 71,683 shares upon the vesting of restricted stock units during the years ended December 31, 2021 and 2020, respectively. In October 2021, the Company entered into an equity distribution agreement under which the Company may sell up to $11.0 million of its shares of common stock in registered “at-the-market” offerings. The shares will be offered at prevailing market prices, and the Company will pay commissions of up to 3.0% of the gross proceeds from the sale of shares sold through the Company’s agent, which may act as an agent and/or principal. The Company has no obligation to sell any shares under this agreement and may, at any time, suspend solicitations under this agreement. No shares of the Company’s common stock have been sold under this distribution agreement during fiscal 2021. Common Stock Warrants In September 2021 and in connection with entering into the Company’s Senior Term Facility (Note 11), the Company issued a warrant to purchase 373,626 shares of the Company’s common stock at an initial exercise price of $1.82 per share. The warrant is equity classified and is exercisable at any time on or prior to the tenth anniversary of its issue date. As of December 31, 2021, the warrant remains outstanding in its entirety.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2021

Stock-Based Compensation [Abstract]

Stock-Based Compensation

14. Stock-Based Compensation

The Company’s 2016 Omnibus Incentive Stock Plan (“2016 Plan”), as amended, has reserved up to 7,832,651 shares of common stock for future issuance. As of December 31, 2021, there were 3,932,271 shares of common stock remaining available for issuance for awards under the 2016 Plan.

The Company measures share‑based awards at their grant‑date fair value and records compensation expense on a straight‑line basis over the requisite service period of the awards. The Company recorded share‑based compensation expense of $1.6 million (for all awards and modifications, if any) for each of the years ended December 31, 2021 and 2020, within general and administrative expenses in the accompanying consolidated statements of operations.

In connection with the separation of the Company’s Chief Executive Officer in February 2021, the Company accelerated the vesting of all unvested options to purchase shares of common stock and extended the period to exercise to August 22, 2021. This acceleration and the extension of the period to vest met the modification criteria for accounting purposes. For these modifications, the Company calculated and recorded additional compensation expense of $0.2 million.

Stock Options

The following table summarizes stock option activity for the years ended December 31, 2021 and 2020:

	Number of Shares under Option Plan			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (in years)
Outstanding at January 1, 2020		4,908,038		$	1.90
Granted		400,000			1.46
Exercised		(15,000	)		1.29
Forfeited and expired		(150	)		170.00
Outstanding at January 1, 2021		5,292,888		$	1.87		7.69
Granted		2,463,714			1.70
Exercised		(1,557,628	)		1.12
Forfeited and expired		(2,260,361	)		2.10
Outstanding at December 31, 2021		3,938,613		$	1.90		7.91
Exercisable at December 31, 2021		1,216,564		$	2.32		4.86

The weighted‑average grant date fair value of options granted was $1.27 and $1.11 per share during the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, the total unrecognized compensation expense related to unvested stock option awards was $2.8 million, which the Company expects to recognize over a weighted‑average period of approximately 2.6 years. The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2021 was $26 thousand and $4 thousand, respectively, and the aggregate intrinsic value of options that were exercised during the year ended December 31, 2021 was $0.5 million. The aggregate intrinsic value of options outstanding and options exercisable at December 31, 2020 was $0.6 million and $0.5 million, respectively, and the aggregate intrinsic value of options that were exercised during the year ended December 31, 2020 was $3 thousand.

During the year ended December 31, 2021, there were 1,557,628 options that were exercised on a cashless basis at $1.12 per share resulting in the net issuance of 329,076 shares of common stock.

The fair value of options is estimated using the Black Scholes option pricing model which takes into account inputs such as the exercise price, the value of the underlying common stock at the grant date, expected term, expected volatility, risk free interest rate and dividend yield. The fair value of each grant of options during the year ended December 31, 2021 and 2020 was determined using the methods and assumptions discussed below.

●

The expected term of employee options is based on the observed and expected time to full-vesting, forfeiture and exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. Options expire up to a maximum of ten years from the date of grant.

●

The expected volatility is based on historical volatility of the Company’s common stock.

●

The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

●

The expected dividend yield is none because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its ordinary shares.

For the years ended December 31, 2021 and 2020, the grant date fair value of all option grants was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions:

	Year Ended December 31,
	2021			2020
Expected term (in years)		5.96			6.00
Expected volatility		90.03	%		94.00	%
Risk-free rate		1.08	%		0.53	%
Dividend rate		0.00	%		0.00	%

Restricted Stock Units

Restricted stock units have been issued to certain board members. Restricted stock units unvested are summarized in the following table:

	Number of Units			Weighted- Average Grant Date Fair Value
Outstanding at January 1, 2020		77,237		$	2.46
Granted		—			—
Vested		(68,091	)		2.46
Forfeited and expired		(9,146	)		2.46
Unvested at January 1, 2021		—		$	—
Granted		290,861			1.44
Vested		(146,364	)		1.42
Forfeited and expired		(53,957	)		1.45
Unvested at December 31, 2021		90,540		$	1.45

As of December 31, 2021, the total unrecognized compensation expense related to unvested restricted stock units was less than $0.1 million, which the Company expects to recognize over a weighted‑average period of approximately 0.5 years.

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Taxes [Abstract]

Income Taxes

15. Income Taxes

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2021			2020
Current:
Federal	$	—		$	—
State		22			21
		22			21
Deferred:
Federal		23			129
State		(11	)		125
		12			254
Income tax expense	$	34		$	275

Deferred tax assets and liabilities are determined based on the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.

Significant components of the Company’s deferred tax liability for federal income taxes consisted of the following:

	December 31,
	2021			2020
Deferred tax assets (liabilities) (in thousands)
Net operating loss carryforwards	$	46,596		$	45,819
Intangible assets		1,039			1,450
Inventory		26			51
Reserves and accrued expenses		1,230			896
Property and equipment		441			(178	)
Stock-based compensation		458			808
Operating lease right-of-use assets		(159	)		(249	)
Goodwill		(950	)		(815	)
Operating lease liability		177			272
481(a) adjustment		(667	)		—
Less: valuation allowance		(48,457	)		(48,308	)
Net deferred tax liability	$	(266	)	$	(254	)

In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more likely than not threshold for realizability. Accordingly, a nearly full valuation allowance has been recorded against the Company’s deferred tax assets as of December 31, 2021 and 2020. The valuation allowance increased by $0.1 million and $1.2 million during the years ended December 31, 2021 and 2020, respectively. The Company does not have unrecognized tax benefits as of December 31, 2021 or 2020. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
Combined NOL carryforwards:	2021		2020
Federal	$	204,314	$	200,976
State	$	60,654	$	43,501

The NOL carryforwards generated prior to 2018 begin expiring in 2022 for federal and 2030 for state income tax purposes. Federal and many state NOLs generated in 2018 and into the future now have an indefinite life.

The NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. To date, the Company has not performed an analysis to determine whether or not ownership changes have occurred since inception.

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	December 31,
Rate reconciliation:	2021			2020
Federal tax expense at statutory rate		21.00	%		21.00	%
State tax, net of federal benefit		(0.33	)%		6.59	%
Permanent differences		8.90	%		(2.75	)%
Other difference and true ups		(25.27	)%		(2.58	)%
Change in valuation allowance		(5.57	)%		(28.90	)%
Tax provision		(1.27	)%		(6.64	)%

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Business and Geographical Reporting Segments

12 Months Ended

Dec. 31, 2021

Business and Geographical Reporting Segments [Abstract]

Business and Geographical Reporting Segments

16. Business and Geographical Reporting Segments

The Company organized its business into two operating segments to better align its organization based upon the Company’s management structure, products and services offered, markets served and types of customers, as follows. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Management reviews financial information presented on an operating segment basis for the purposes of making certain operating decisions and assessing financial performance.

Unallocated operating expenses include costs that are not specific to a particular segment but are general to the group; included are expenses incurred for administrative and accounting staff, general liability and other insurance, professional fees and other similar corporate expenses. Interest and other financing income (expense) is also not allocated to the operating segments.

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2021	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	22,528		$	7,449		$	29,977
Cost of revenues		6,418			3,709			10,127
Gross profit		16,110			3,740			19,850
Gross profit %		71.5	%		50.2	%		66.2	%

Allocated expenses:
Engineering and product development		1,251			183			1,434
Selling and marketing		12,257			849			13,106
Unallocated expenses		—			—			9,712
		13,508			1,032			24,252
Income (loss) from operations		2,602			2,708			(4,402	)
Interest expense		—			—			(314	)
Interest income		—			—			15
Gain on debt extinguishment		—			—			2,029
Income (loss) before income tax expense	$	2,602		$	2,708		$	(2,672	)

Year Ended December 31, 2020	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	17,409		$	5,681		$	23,090
Cost of revenues		5,832			3,124			8,956
Gross profit		11,577			2,557			14,134
Gross profit %		66.5	%		45.0	%		61.2	%

Allocated expenses:
Engineering and product development		1,101			173			1,274
Selling and marketing		8,437			601			9,038
Unallocated expenses		—			—			7,898
		9,538			774			18,210
Income (loss) from operations		2,039			1,783			(4,076	)
Interest expense		—			—			(211	)
Interest income		—			—			150
Income (loss) before income tax expense	$	2,039		$	1,783		$	(4,137	)

The following table presents the Company’s revenue disaggregated by geographical region for the years ended December 31, 2021 and 2020. Domestic refers to revenue from customers based in the United States, and foreign recurring revenue is derived from the Company’s distributors primarily in Asia.

Year Ended December 31, 2021	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	21,215	$	1,982	$	23,197
Foreign		1,313		5,467		6,780
Total	$	22,528	$	7,449	$	29,977

Year Ended December 31, 2020	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	16,848	$	956	$	17,804
Foreign		561		4,725		5,286
Total	$	17,409	$	5,681	$	23,090

As of December 31, 2021 and 2020, total assets by reportable segment were as follows:

	December 31,
	2021		2020
Assets:
Dermatology recurring procedures	$	30,897	$	25,112
Dermatology procedures equipment		2,662		3,052
Other unallocated assets		13,034		18,614
Consolidated total	$	46,593	$	46,778

Long-lived assets of $1.0 million and $0.5 million were located in international markets as of December 31, 2021 and 2020, respectively, with the remainder located in domestic markets.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events TheraClear In January 2022, the Company acquired certain assets related to the TheraClear Devices from Theravant Corporation. The TheraClear asset acquisition will allow the Company to further develop, commercialize and market the TheraClear Devices that are used for acne treatment, as well as advance the TheraClear technology into multiple other devices that can be used to treat a range of additional indications. The Company made an upfront cash payment of $0.5 million and issued to Theravant Corporation 358,367 shares of common stock with an aggregate value of $0.5 million in connection with the TheraClear asset acquisition. Theravant Corporation is eligible to receive up to $3.0 million in future earnout payments upon the achievement of certain annual net revenue milestones, up to $20.0 million in future royalty payments based upon gross profit from future domestic sales, 25% of gross profit from international sales over the subsequent four-year period, and up to $1.0 million in future milestone payments upon the achievement of certain development and related net revenue targets.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Use of Estimates

Reclassifications

Certain reclassifications from the prior year presentation have been made to conform to the current year presentation.

Concentrations of Credit Risk and Major Customers

Cash and Cash Equivalents

Restricted Cash

	December 31,
	2021		2020
Cash and cash equivalents	$	12,586	$	10,604
Restricted cash		—		7,508
Total cash and restricted cash presented in the consolidated statements of cash flows	$	12,586	$	18,112

Accounts Receivable and Allowance for Doubtful Accounts

Inventories

Property and Equipment

Intangible Assets

Goodwill

Impairment of Long-Lived Assets and Intangibles

Fair Value Measurements

•	Level 1 – quoted market prices in active markets for identical assets or liabilities.

•

•	Level 3 – inputs that are generally unobservable and typically reflect the Company’s estimate of assumptions that market participants would use in pricing the asset or liability.

Accrued Warranty Costs

	December 31,
	2021			2020
Balance, beginning of year	$	113		$	232
Additions		71			67
Expirations and claims satisfied		(105	)		(186	)
Total		79			113
Less current portion within accrued expenses and other current liabilities		(59	)		(87	)
Balance within deferred revenues and other liabilities	$	20		$	26

Debt Issuance Costs

Revenue Recognition

•

identification of the contract, or contracts, with a customer;

•

identification of the performance obligations in the contract;

•

determination of the transaction price;

•

allocation of the transaction price to the performance obligations in the contract; and

•

recognition of revenue when, or as, performance obligations are satisfied.

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2021		2020
Dermatology recurring procedures	$	22,528	$	17,409
Dermatology procedures equipment		7,449		5,681
Total net revenues	$	29,977	$	23,090

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from dermatology recurring procedures (in thousands):

Years ending December 31:
2022	$	1,680
2023		1,624
2024		1,303
2025		530
2026		4
	$	5,141

With respect to contract acquisition costs, the Company applied the practical expedient and expenses these costs immediately.

Engineering and Product Development

Engineering and product development costs associated with research, new product development and product redesign are expensed as incurred.

Advertising Costs

Stock-Based Compensation

The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the requisite service period of the awards.

Income Taxes

Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2021		2020
Unvested restricted stock units		90,540		—
Stock options		3,938,613		5,292,888
Common stock warrants		373,626		19,812
		4,402,779		5,312,700

Recent Accounting Pronouncements

Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2021		2020
Cash and cash equivalents	$	12,586	$	10,604
Restricted cash		—		7,508
Total cash and restricted cash presented in the consolidated statements of cash flows	$	12,586	$	18,112

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2021 and 2020 is summarized as follows (in thousands):

	December 31,
	2021			2020
Balance, beginning of year	$	113		$	232
Additions		71			67
Expirations and claims satisfied		(105	)		(186	)
Total		79			113
Less current portion within accrued expenses and other current liabilities		(59	)		(87	)
Balance within deferred revenues and other liabilities	$	20		$	26

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2021		2020
Dermatology recurring procedures	$	22,528	$	17,409
Dermatology procedures equipment		7,449		5,681
Total net revenues	$	29,977	$	23,090

Future Undiscounted Fixed Treatment Code Payments

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from dermatology recurring procedures (in thousands):

Years ending December 31:
2022	$	1,680
2023		1,624
2024		1,303
2025		530
2026		4
	$	5,141

Antidilutive Securities Excluded from Computation of Earnings (Loss) Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2021		2020
Unvested restricted stock units		90,540		—
Stock options		3,938,613		5,292,888
Common stock warrants		373,626		19,812
		4,402,779		5,312,700

Pharos Asset Acquisition (Tables)

12 Months Ended

Dec. 31, 2021

Pharos Asset Acquisition [Abstract]

Purchase Price Allocation

The purchase price was allocated, on a relative fair value basis, to the acquired inventory, customer lists and deferred revenues as follows (in thousands):

Consideration:
Cash payment	$	3,700
Transaction costs		57
Total consideration	$	3,757
Assets acquired:
Inventory	$	284
Customer lists		5,314
Total assets acquired	$	5,598
Liabilities assumed:
Deferred revenues – service contracts	$	1,841
Total liabilities assumed	$	1,841

Net assets acquired

3,757

Inventories (Tables)

12 Months Ended

Dec. 31, 2021

Inventories [Abstract]

Inventories

Inventories consist of the following (in thousands):

	December 31,
	2021		2020
Raw materials and work-in-process	$	3,201	$	2,949
Finished goods		288		495
	$	3,489	$	3,444

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property and Equipment [Abstract]

Components of Property and Equipment

Property and equipment consist of the following (in thousands):

	December 31,
	2021			2020
Lasers placed-in-service	$	25,949		$	22,942
Equipment, computer hardware and software		238			146
Furniture and fixtures		213			243
Leasehold improvements		254			43
		26,654			23,374
Less: accumulated depreciation and amortization		(19,771	)		(17,845	)
	$	6,883		$	5,529

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Operating Lease Maturities

The following table summarizes the Company’s operating lease maturities as of December 31, 2021 (in thousands):

Years ending December 31:
2022	$	371
2023		242
2024		186
Total remaining lease payments		799
Less: imputed interest		(89	)
Total lease liabilities	$	710

Intangible Assets and Goodwill (Tables)

12 Months Ended

Dec. 31, 2021

Intangible Assets and Goodwill [Abstract]

Components of Intangible Assets

Intangible assets consist of the following (in thousands):

December 31, 2021	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(3,705	)	$	1,995
Product technology		2,000		(2,000	)		—
Customer relationships		6,900		(4,485	)		2,415
Tradenames		1,500		(975	)		525
Pharos customer lists		5,314		(166	)		5,148
	$	21,414	$	(11,331	)	$	10,083

December 31, 2020	Balance		Accumulated Amortization			Net Book Value
Core technology	$	5,700	$	(3,135	)	$	2,565
Product technology		2,000		(2,000	)		—
Customer relationships		6,900		(3,795	)		3,105
Tradenames		1,500		(825	)		675
	$	16,100	$	(9,755	)	$	6,345

Estimated Future Amortization Expense for Intangible Assets

The following table summarizes the estimated future amortization expense for the above intangible assets for the next five years (in thousands):

Years ending December 31:
2022	$	1,853
2023		1,853
2024		1,853
2025		1,148
2026		443

Components of Goodwill

Goodwill consists of the following (in thousands):

	December 31,
	2021		2020
Dermatology recurring procedures segment	$	7,958	$	7,958
Dermatology procedures equipment segment		845		845
	$	8,803	$	8,803

Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Accrued Expenses and Other Current Liabilities [Abstract]

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	December 31,
	2021		2020
Warranty obligations	$	59	$	87
Compensation and related benefits		2,052		891
State sales, use and other taxes		3,697		3,105
Professional fees and other		569		607
	$	6,377	$	4,690

Long-term Debt (Tables)

12 Months Ended

Dec. 31, 2021

Long-term Debt [Abstract]

Future Payments for Long-term Debt

Future minimum principal payments at December 31, 2021 are as follows (in thousands):

Years ending December 31:
2024	$	1,000
2025		4,000
2026		3,000
	$	8,000

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Stock-Based Compensation [Abstract]

Stock Option Activity

The following table summarizes stock option activity for the years ended December 31, 2021 and 2020:

	Number of Shares under Option Plan			Weighted- Average Exercise Price per Option		Weighted- Average Remaining Contractual Life (in years)
Outstanding at January 1, 2020		4,908,038		$	1.90
Granted		400,000			1.46
Exercised		(15,000	)		1.29
Forfeited and expired		(150	)		170.00
Outstanding at January 1, 2021		5,292,888		$	1.87		7.69
Granted		2,463,714			1.70
Exercised		(1,557,628	)		1.12
Forfeited and expired		(2,260,361	)		2.10
Outstanding at December 31, 2021		3,938,613		$	1.90		7.91
Exercisable at December 31, 2021		1,216,564		$	2.32		4.86

Weighted Average Assumption Used for Grant Date Fair Value of Option Grants

	Year Ended December 31,
	2021			2020
Expected term (in years)		5.96			6.00
Expected volatility		90.03	%		94.00	%
Risk-free rate		1.08	%		0.53	%
Dividend rate		0.00	%		0.00	%

Summary of Restricted Stock Unit Unvested

Restricted stock units have been issued to certain board members. Restricted stock units unvested are summarized in the following table:

	Number of Units			Weighted- Average Grant Date Fair Value
Outstanding at January 1, 2020		77,237		$	2.46
Granted		—			—
Vested		(68,091	)		2.46
Forfeited and expired		(9,146	)		2.46
Unvested at January 1, 2021		—		$	—
Granted		290,861			1.44
Vested		(146,364	)		1.42
Forfeited and expired		(53,957	)		1.45
Unvested at December 31, 2021		90,540		$	1.45

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Taxes [Abstract]

Components of Income Tax Expense

Income tax expense consists of the following (in thousands):

	Year Ended December 31,
	2021			2020
Current:
Federal	$	—		$	—
State		22			21
		22			21
Deferred:
Federal		23			129
State		(11	)		125
		12			254
Income tax expense	$	34		$	275

Components of Deferred Tax Liability for Federal Income Taxes

Significant components of the Company’s deferred tax liability for federal income taxes consisted of the following:

	December 31,
	2021			2020
Deferred tax assets (liabilities) (in thousands)
Net operating loss carryforwards	$	46,596		$	45,819
Intangible assets		1,039			1,450
Inventory		26			51
Reserves and accrued expenses		1,230			896
Property and equipment		441			(178	)
Stock-based compensation		458			808
Operating lease right-of-use assets		(159	)		(249	)
Goodwill		(950	)		(815	)
Operating lease liability		177			272
481(a) adjustment		(667	)		—
Less: valuation allowance		(48,457	)		(48,308	)
Net deferred tax liability	$	(266	)	$	(254	)

Net Operating Loss Carryforwards

The Company had net operating loss (“NOL”) carryforwards for federal and state income tax purposes as follows (in thousands):

	December 31,
Combined NOL carryforwards:	2021		2020
Federal	$	204,314	$	200,976
State	$	60,654	$	43,501

Reconciliation of Income Tax Expense

A reconciliation of income tax expense at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:

	December 31,
Rate reconciliation:	2021			2020
Federal tax expense at statutory rate		21.00	%		21.00	%
State tax, net of federal benefit		(0.33	)%		6.59	%
Permanent differences		8.90	%		(2.75	)%
Other difference and true ups		(25.27	)%		(2.58	)%
Change in valuation allowance		(5.57	)%		(28.90	)%
Tax provision		(1.27	)%		(6.64	)%

Business and Geographical Reporting Segments (Tables)

12 Months Ended

Dec. 31, 2021

Business and Geographical Reporting Segments [Abstract]

Segment Reporting Information by Segment

The following tables reflect results of operations from our business segments for the periods indicated below:

Year Ended December 31, 2021	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	22,528		$	7,449		$	29,977
Cost of revenues		6,418			3,709			10,127
Gross profit		16,110			3,740			19,850
Gross profit %		71.5	%		50.2	%		66.2	%

Allocated expenses:
Engineering and product development		1,251			183			1,434
Selling and marketing		12,257			849			13,106
Unallocated expenses		—			—			9,712
		13,508			1,032			24,252
Income (loss) from operations		2,602			2,708			(4,402	)
Interest expense		—			—			(314	)
Interest income		—			—			15
Gain on debt extinguishment		—			—			2,029
Income (loss) before income tax expense	$	2,602		$	2,708		$	(2,672	)

Year Ended December 31, 2020	Dermatology Recurring Procedures			Dermatology Procedures Equipment			Total
Revenues	$	17,409		$	5,681		$	23,090
Cost of revenues		5,832			3,124			8,956
Gross profit		11,577			2,557			14,134
Gross profit %		66.5	%		45.0	%		61.2	%

Allocated expenses:
Engineering and product development		1,101			173			1,274
Selling and marketing		8,437			601			9,038
Unallocated expenses		—			—			7,898
		9,538			774			18,210
Income (loss) from operations		2,039			1,783			(4,076	)
Interest expense		—			—			(211	)
Interest income		—			—			150
Income (loss) before income tax expense	$	2,039		$	1,783		$	(4,137	)

Disaggregation of Revenue by Geographical Region

Year Ended December 31, 2021	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	21,215	$	1,982	$	23,197
Foreign		1,313		5,467		6,780
Total	$	22,528	$	7,449	$	29,977

Year Ended December 31, 2020	Dermatology Recurring Procedures		Dermatology Procedures Equipment		Total
Domestic	$	16,848	$	956	$	17,804
Foreign		561		4,725		5,286
Total	$	17,409	$	5,681	$	23,090

Total Assets by Reportable Segment

As of December 31, 2021 and 2020, total assets by reportable segment were as follows:

	December 31,
	2021		2020
Assets:
Dermatology recurring procedures	$	30,897	$	25,112
Dermatology procedures equipment		2,662		3,052
Other unallocated assets		13,034		18,614
Consolidated total	$	46,593	$	46,778

Organization and Nature of Business (Details) $ in Millions	1 Months Ended
Organization and Nature of Business (Details) $ in Millions	Oct. 31, 2021 USD ($)
At-the-Market Equity Offering [Member] \| Maximum [Member]
Liquidity and Going Concern [Abstract]
Amount of common stock the Company may sell under equity distribution agreement	$ 11.0

Basis of Presentation and Summary of Significant Accounting Policies, Concentrations of Credit Risk and Major Customers (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) Customer	Dec. 31, 2020 USD ($)
Concentration of Credit Risk [Abstract]
Revenues	$ 29,977	$ 23,090
Customer Concentration Risk [Member] \| Revenue [Member]
Concentration of Credit Risk [Abstract]
Number of major customers \| Customer	1
Customer Concentration Risk [Member] \| Revenue [Member] \| Customer One [Member]
Concentration of Credit Risk [Abstract]
Revenues	$ 3,400
Concentration risk percentage	11.00%
Customer Concentration Risk [Member] \| Revenue [Member] \| Former International Master Distributor [Member]
Concentration of Credit Risk [Abstract]
Revenues		$ 2,700
Concentration risk percentage		12.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member] \| Maximum [Member]
Concentration of Credit Risk [Abstract]
Concentration risk percentage	10.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Former International Master Distributor [Member] \| Maximum [Member]
Concentration of Credit Risk [Abstract]
Concentration risk percentage		10.00%

Basis of Presentation and Summary of Significant Accounting Policies, Cash and Cash Equivalents (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Maximum [Member]
Cash and Cash Equivalents, at Carrying Value [Abstract]
Credit card transaction settlement term	5 days	5 days

Basis of Presentation and Summary of Significant Accounting Policies, Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Restricted Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 12,586	$ 10,604
Restricted cash	0	7,508
Total cash and restricted cash presented in the consolidated statements of cash flows	$ 12,586	$ 18,112	$ 15,629

Basis of Presentation and Summary of Significant Accounting Policies, Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Computers, Hardware and Software [Member]
Property and Equipment [Abstract]
Property and equipment, useful life	3 years
Machinery and Equipment [Member]
Property and Equipment [Abstract]
Property and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property and Equipment [Abstract]
Property and equipment, useful life	7 years

Basis of Presentation and Summary of Significant Accounting Policies, Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2021
Minimum [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life	3 years
Maximum [Member]
Finite-Lived Intangible Assets, Net [Abstract]
Estimated useful life	12 years

Basis of Presentation and Summary of Significant Accounting Policies, Goodwill (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) Unit	Dec. 31, 2020 USD ($)
Goodwill [Abstract]
Number of reporting units \| Unit	2
Goodwill impairment \| $	$ 0	$ 0

Basis of Presentation and Summary of Significant Accounting Policies, Impairment of Long-Lived Assets and Intangibles (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Impairment of Long-Lived Assets and Intangibles [Abstract]
Asset impairment charges	$ 0	$ 0

Basis of Presentation and Summary of Significant Accounting Policies, Accrued Warranty Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Activity of Warranty Accrual [Roll Forward]
Balance, beginning of year	$ 113	$ 232
Additions	71	67
Expirations and claims satisfied	(105)	(186)
Total	79	113
Less current portion within accrued expenses and other current liabilities	(59)	(87)
Balance within deferred revenues and other liabilities	$ 20	$ 26
Minimum [Member]
Product Warranty Liability [Line Items]
Standard warranty period	1 year
Offered warranty period	3 years
Maximum [Member]
Product Warranty Liability [Line Items]
Standard warranty period	2 years
Offered warranty period	4 years

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2021
Lasers Placed-in Service [Member]
Revenue Recognition [Abstract]
Lease term	36 months
Renewal term	1 year
Lasers Placed-in Service [Member] \| Minimum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	30 days
Lasers Placed-in Service [Member] \| Maximum [Member]
Revenue Recognition [Abstract]
Notice period to cancel contract agreement	60 days
South Korea [Member]
Revenue Recognition [Abstract]
Lease term	48 months

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Abstract]
Revenues, net	$ 29,977	$ 23,090
Dermatology Recurring Procedures [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	22,528	17,409
Dermatology Procedures Equipment [Member]
Disaggregation of Revenue [Abstract]
Revenues, net	$ 7,449	$ 5,681

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Future Undiscounted Fixed Treatment Code Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 26	$ 115
Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	5,141
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers		$ 108
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 12
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,680
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,624
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 1,303
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 530
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 \| Dermatology Recurring Procedures [Member]
Revenue, Performance Obligation Satisfied over Time [Abstract]
Future undiscounted fixed payments from international recurring revenue customers	$ 4
Expected timing of satisfaction period	1 year

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Remaining Performance Obligation (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 26	$ 115
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations		$ 108
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Remaining Performance Obligation [Abstract]
Remaining performance obligations	$ 12
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period		1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period		3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Minimum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 \| Maximum [Member]
Remaining Performance Obligation [Abstract]
Expected timing of satisfaction period	3 years

Basis of Presentation and Summary of Significant Accounting Policies, Revenue Recognition, Contract Liabilities (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2021
Contract with Customer, Liability [Abstract]
Short-term contract liabilities	$ 108		$ 12
Long-term contract liabilities	7		$ 14
Change in Contract with Customer, Liability [Abstract]
Contract liabilities recognized as revenue	$ 100	$ 200

Basis of Presentation and Summary of Significant Accounting Policies, Advertising Costs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Advertising Costs [Abstract]
Advertising expense	$ 1.6	$ 0.7

Basis of Presentation and Summary of Significant Accounting Policies, Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	4,402,779	5,312,700
Unvested Restricted Stock Units [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	90,540	0
Stock Options [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	3,938,613	5,292,888
Common Stock Warrants [Member]
Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]
Potential common stock equivalents (in shares)	373,626	19,812

Pharos Asset Acquisition (Details) - RA Medical Systems, Inc. [Member] $ in Thousands	1 Months Ended	12 Months Ended
	Aug. 31, 2021 USD ($) Practice	Dec. 31, 2021
Acquisition of Assets and Liabilities [Abstract]
Number of dermatology practices \| Practice	400
Consideration [Abstract]
Cash payment	$ 3,700
Transaction costs	57
Total consideration	3,757
Assets acquired [Abstract]
Inventory	284
Total assets acquired	5,598
Liabilities assumed [Abstract]
Deferred revenues - service contracts	1,841
Total liabilities assumed	1,841
Net assets acquired	$ 3,757
Estimated customer sales growth	3.00%
Customer attrition	5.00%
Weighted average cost of capital	17.00%
Customer Lists [Member]
Assets acquired [Abstract]
Intangible assets	$ 5,314
Liabilities assumed [Abstract]
Amortization period of intangible assets		12 years

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Schedule of inventory [Abstract]
Raw materials and work in process	$ 3,201	$ 2,949
Finished goods	288	495
Inventories, net	$ 3,489	$ 3,444

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 26,654	$ 23,374
Less: accumulated depreciation and amortization	(19,771)	(17,845)
Property and equipment, net	6,883	5,529
Depreciation and amortization expense	2,100	2,000
Lasers Placed-In-Service [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	25,949	22,942
Equipment, Computer Hardware and Software [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	238	146
Furniture and Fixtures [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	213	243
Leasehold Improvements [Member]
Property, Plant and Equipment, Net [Abstract]
Property and equipment, gross	$ 254	$ 43

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Lessee, Operating Lease, Description [Abstract]
Operating lease costs	$ 400	$ 400
Cash paid for amounts included in measurement of operating lease liabilities	$ 500	$ 400
Incremental borrowing rate	9.76%	9.76%
Weighted average remaining lease term	2 years 3 months 18 days	3 years 1 month 6 days
Operating Lease Maturities [Abstract]
2022	$ 371
2023	242
2024	186
Total remaining lease payments	799
Less: imputed interest	(89)
Total lease liabilities	$ 710
Minimum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	1 year
Maximum [Member]
Lessee, Operating Lease, Description [Abstract]
Remaining lease term	3 years
Facility One [Member]
Lessee, Operating Lease, Description [Abstract]
Renewal option term	2 years

Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Components of Intangible Assets [Abstract]
Balance	$ 21,414	$ 16,100
Accumulated amortization	(11,331)	(9,755)
Intangible assets, net	10,083	6,345
Amortization expense of intangible assets	1,600	1,600
Core Technology [Member]
Components of Intangible Assets [Abstract]
Balance	5,700	5,700
Accumulated amortization	(3,705)	(3,135)
Intangible assets, net	1,995	2,565
Product Technology [Member]
Components of Intangible Assets [Abstract]
Balance	2,000	2,000
Accumulated amortization	(2,000)	(2,000)
Intangible assets, net	0	0
Customer Relationships [Member]
Components of Intangible Assets [Abstract]
Balance	6,900	6,900
Accumulated amortization	(4,485)	(3,795)
Intangible assets, net	2,415	3,105
Tradenames [Member]
Components of Intangible Assets [Abstract]
Balance	1,500	1,500
Accumulated amortization	(975)	(825)
Intangible assets, net	525	$ 675
Pharos Customer Lists [Member]
Components of Intangible Assets [Abstract]
Balance	5,314
Accumulated amortization	(166)
Intangible assets, net	$ 5,148

Intangible Assets and Goodwill, Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Estimated amortization expense [Abstract]
2022	$ 1,853
2023	1,853
2024	1,853
2025	1,148
2026	$ 443

Intangible Assets and Goodwill, Components of Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Components of Goodwill [Abstract]
Goodwill	$ 8,803	$ 8,803
Dermatology Recurring Procedures [Member]
Components of Goodwill [Abstract]
Goodwill	7,958	7,958
Dermatology Procedures Equipment [Member]
Components of Goodwill [Abstract]
Goodwill	$ 845	$ 845

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses and Other Current Liabilities [Abstract]
Warranty obligations	$ 59	$ 87
Compensation and related benefits	2,052	891
State sales, use and other taxes	3,697	3,105
Professional fees and other	569	607
Accrued expenses and other current liabilities	$ 6,377	$ 4,690

Note Payable (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
Note Payable (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Debt Instruments [Abstract]
Repayments of notes payable		$ 7,275	$ 0
Note [Member]
Debt Instruments [Abstract]
Face amount of debt			$ 7,300
Debt instrument term		1 year
Maturity date		Dec. 30, 2021
Fixed interest rate			1.40%
Repayments of notes payable	$ 7,300
Time Deposit [Member]
Debt Instruments [Abstract]
Fixed interest rate			0.40%

Long-term Debt, Senior Term Facility (Details) - Senior Term Facility [Member] $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended	12 Months Ended
	Sep. 30, 2021 $ / shares shares	Sep. 30, 2021 USD ($) $ / shares	Dec. 31, 2021 USD ($) Payment $ / shares shares
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares	373,626
Warrants, exercise price (in dollars per share) \| $ / shares	$ 1.82	$ 1.82
MidCap Financial Trust [Member]
Long-term Debt [Abstract]
Face amount of debt			$ 8.0
Interest rate percentage			8.00%
Maturity date			Sep. 01, 2026
Number of monthly principal payments plus interest \| Payment			24
Frequency of payment			monthly
Notice period			30 days
Prepayment fee if prepayment is made within twelve months			4.00%
Prepayment fee if prepayment is made between twelve months and twenty-four months			3.00%
Prepayment fee if prepayment is made between twenty-four months and thirty-six months			2.00%
Prepayment fee if prepayment is made after thirty-six months			1.00%
Minimum net revenue threshold		$ 24.0	$ 25.0
Minimum net revenue threshold by December 31, 2023			30.0
Estimated fair value of warrants			0.6
Third party costs and lender fees			0.1
Unamortized debt discount			0.7
Interest expense			0.3
Amortization of debt discount			37.0
MidCap Financial Trust [Member] \| Minimum [Member]
Long-term Debt [Abstract]
Prepayment of debt			$ 5.0
MidCap Financial Trust [Member] \| Common Stock [Member]
Long-term Debt [Abstract]
Warrants issued (in shares) \| shares			373,626
Warrants, exercise price (in dollars per share) \| $ / shares			$ 1.82
MidCap Financial Trust [Member] \| LIBOR [Member]
Long-term Debt [Abstract]
Interest rate floor			0.50%
Basis spread on variable rate			7.50%
MidCap Financial Trust [Member] \| Expected Volatility [Member]
Long-term Debt [Abstract]
Warrants, expected term			10 years
Warrants, measurement input			0.886
MidCap Financial Trust [Member] \| Risk-Free Rate [Member]
Long-term Debt [Abstract]
Warrants, measurement input			0.0150
MidCap Financial Trust [Member] \| Estimated Dividend Yield [Member]
Long-term Debt [Abstract]
Warrants, measurement input			0

Long-term Debt, Future Minimum Principal Payments (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Future Payments for Long-Term Debt [Abstract]
2024	$ 1,000
2025	4,000
2026	3,000
Future minimum principal payments	$ 8,000

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

Long-term Debt, PPP Loan and EIDL Loan (Details) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
	May 22, 2020	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Apr. 22, 2020
Long-term Debt [Abstract]
Gain on forgiveness of debt			$ 2,029	$ 0
PPP Loans [Member]
Long-term Debt [Abstract]
Face amount of debt					$ 2,000
Maturity date			May 01, 2022
Interest rate percentage					1.00%
Gain on forgiveness of debt		$ 2,000
EDIL [Member]
Long-term Debt [Abstract]
Face amount of debt	$ 500
Interest rate percentage	3.75%
Installment monthly payment amount	$ 2
Debt instrument term			30 years

Commitments and Contingencies (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee 401(k) Savings Plan [Abstract]
Employer contribution amount	$ 0.3	$ 0.2
Tax Period from March 2014 through April 2020 [Member]
Sales and Use Tax Matters [Abstract]
Estimated tax positions subject to audit	2.4
Tax Period from March 2014 through April 2020 [Member] \| Assessment One [Member]
Sales and Use Tax Matters [Abstract]
Assessment amount	1.5
Tax Period from March 2014 through April 2020 [Member] \| Assessment Two [Member]
Sales and Use Tax Matters [Abstract]
Assessment amount	$ 0.9

Stockholders' Equity, Preferred Stock and Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Oct. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Class of Stock Disclosures [Abstract]
Preferred stock, stated value (in dollars per share)		$ 0.10	$ 0.10
Preferred shares outstanding (in shares)		0	0
Stock issued upon exercise of stock options (in shares)		329,076	15,000
Issuance of restricted stock (in shares)		234,558	71,683
At-the-Market Equity Offering [Member]
Class of Stock Disclosures [Abstract]
Common stock sold under equity distribution agreement (in shares)		0
At-the-Market Equity Offering [Member] \| Maximum [Member]
Class of Stock Disclosures [Abstract]
Amount of common stock the Company may sell under equity distribution agreement	$ 11.0
Commission as percentage of gross proceeds from sale of shares sold	3.00%
Series C Convertible Preferred Stock [Member]
Class of Stock Disclosures [Abstract]
Beneficial ownership percentage		9.99%
Preferred stock, stated value (in dollars per share)		$ 1,000
Preferred stock conversion price (in dollars per share)		$ 2.69
Number of common shares issuable on conversion of preferred stock (in shares)			2,103
Number of common shares issued on conversion of preferred stock (in shares)			782,089

Stockholders' Equity, Outstanding Common Stock Warrants (Details) - Senior Term Facility [Member]	1 Months Ended
	Sep. 30, 2021 $ / shares shares
Warrants and Rights [Abstract]
Warrants issued (in shares) \| shares	373,626
Exercise price (in dollars per share) \| $ / shares	$ 1.82

Stock-based Compensation, Summary (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 28, 2021	Dec. 31, 2021	Dec. 31, 2020
Stock-based Compensation [Abstract]
Stock-based compensation expense		$ 1,643	$ 1,633
Accelerated compensation expense	$ 200
2016 Omnibus Incentive Plan [Member]
Stock-based Compensation [Abstract]
Common stock reserved for future issuance (in shares)		7,832,651
Number of shares available for issuance (in shares)		3,932,271

Stock-Based Compensation, Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Shares under Options Plan [Abstract]
Exercised (in shares)	(329,076)	(15,000)
Weighted average remaining contractual term [Abstract]
Exercisable	6 months
Maximum [Member]
Weighted average remaining contractual term [Abstract]
Unrecognized compensation expense	$ 100
Stock Options [Member]
Number of Shares under Options Plan [Abstract]
Outstanding at beginning of period (in shares)	5,292,888	4,908,038
Granted (in shares)	2,463,714	400,000
Exercised (in shares)	(1,557,628)	(15,000)
Forfeited and expired (in shares)	(2,260,361)	(150)
Outstanding at end of period (in shares)	3,938,613	5,292,888
Exercisable at end of period (in shares)	1,216,564
Weighted Average Exercise Price per Option [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 1.87	$ 1.90
Granted (in dollars per share)	1.70	1.46
Exercised (in dollars per share)	1.12	1.29
Forfeited and expired (in dollars per share)	2.10	170.00
Outstanding at end of period (in dollars per share)	1.90	$ 1.87
Exercisable at end of period (in dollars per share)	$ 2.32
Weighted average remaining contractual term [Abstract]
Outstanding	7 years 10 months 28 days	7 years 8 months 8 days
Exercisable	4 years 10 months 9 days
Weighted-average grant date fair value (in dollars per share)	$ 1.27	$ 1.11
Unrecognized compensation expense	$ 2,800
Unrecognized compensation expense, weighted average period	2 years 7 months 6 days
Aggregate intrinsic value of options outstanding	$ 26	$ 600
Aggregate intrinsic value of options exercisable	4	500
Aggregate intrinsic value of options exercised	$ 500	$ 3
Stock option exercise, stock issued (in shares)	329,076
Stock Options [Member] \| Maximum [Member]
Weighted average remaining contractual term [Abstract]
Expiration period	10 years

Stock-Based Compensation, Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value Assumptions [Abstract]
Expected term (in years)	5 years 11 months 15 days	6 years
Expected volatility	90.03%	94.00%
Risk-free rate	1.08%	0.53%
Dividend rate	0.00%	0.00%

Stock-Based Compensation, Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Unrecognized Compensation Expense [Abstract]
Weighted average period of recognition	6 months
Maximum [Member]
Unrecognized Compensation Expense [Abstract]
Unrecognized compensation expense	$ 0.1
Restricted Stock Units [Member]
Number of Units [Abstract]
Unvested balance at beginning of period (in shares)	0	77,237
Granted (in shares)	290,861	0
Vested (in shares)	(146,364)	(68,091)
Forfeited and expired (in shares)	(53,957)	(9,146)
Unvested balance at end of period (in shares)	90,540	0
Weighted-Average Grant Date Fair Value [Abstract]
Unvested balance at beginning of period (in dollars per share)	$ 0	$ 2.46
Granted (in dollars per share)	1.44	0
Vested (in dollars per share)	1.42	2.46
Forfeited and expired (in dollars per share)	1.45	2.46
Unvested balance at end of period (in dollars per share)	$ 1.45	$ 0

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current [Abstract]
Federal	$ 0	$ 0
State	22	21
Current income tax	22	21
Deferred [Abstract]
Federal	23	129
State	(11)	125
Deferred income tax	12	254
Income tax expense	34	275
Deferred Tax Assets (Liabilities) [Abstract]
Net operating loss carryforwards	46,596	45,819
Intangible assets	1,039	1,450
Inventory	26	51
Reserves and accrued expenses	1,230	896
Property and equipment	441
Property and equipment		(178)
Stock-based compensation	458	808
Operating lease right-of-use assets	(159)	(249)
Goodwill	(950)	(815)
Operating lease liability	177	272
481(a) adjustment	(667)	0
Less: valuation allowance	(48,457)	(48,308)
Net deferred tax liability	(266)	(254)
Valuation allowance - Deferred tax asset change in amount	100	1,200
Unrecognized tax benefits	$ 0	$ 0
Effective Income Tax Rate Reconciliation [Abstract]
Federal tax expense at statutory rate	21.00%	21.00%
State tax, net of federal benefit	(0.33%)	6.59%
Permanent differences	8.90%	(2.75%)
Other difference and true ups	(25.27%)	(2.58%)
Change in valuation allowance	(5.57%)	(28.90%)
Tax provision	(1.27%)	(6.64%)
Federal [Member]
Operating Loss Carryforwards [Abstract]
Operating loss carryforwards	$ 204,314	$ 200,976
State [Member]
Operating Loss Carryforwards [Abstract]
Operating loss carryforwards	$ 60,654	$ 43,501

Business and Geographical Reporting Segments (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) Segment	Dec. 31, 2020 USD ($)
Business Segments [Abstract]
Number of operating segments \| Segment	2
Results of Operations from Business Segments [Abstract]
Revenues	$ 29,977	$ 23,090
Cost of revenues	10,127	8,956
Gross profit	$ 19,850	$ 14,134
Gross profit %	66.20%	61.20%
Allocated expenses [Abstract]
Engineering and product development	$ 1,434	$ 1,274
Selling and marketing	13,106	9,038
Unallocated expenses	9,712	7,898
Total operating expenses	24,252	18,210
Income (loss) from operations	(4,402)	(4,076)
Interest expense	(314)	(211)
Interest income	15	150
Gain on debt extinguishment	2,029
Loss before income tax expense	(2,672)	(4,137)
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	29,977	23,090
Total Assets by Reportable Segment [Abstract]
Assets	46,593	46,778
Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	22,528	17,409
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	22,528	17,409
Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	7,449	5,681
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	7,449	5,681
Domestic [Member]
Results of Operations from Business Segments [Abstract]
Revenues	23,197	17,804
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	23,197	17,804
Foreign [Member]
Results of Operations from Business Segments [Abstract]
Revenues	6,780	5,286
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	6,780	5,286
Long-lived Assets [Abstract]
Long-lived assets	1,000	500
Operating Segments [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	22,528	17,409
Cost of revenues	6,418	5,832
Gross profit	$ 16,110	$ 11,577
Gross profit %	71.50%	66.50%
Allocated expenses [Abstract]
Engineering and product development	$ 1,251	$ 1,101
Selling and marketing	12,257	8,437
Unallocated expenses	0	0
Total operating expenses	13,508	9,538
Income (loss) from operations	2,602	2,039
Interest expense	0	0
Interest income	0	0
Gain on debt extinguishment	0
Loss before income tax expense	2,602	2,039
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	22,528	17,409
Total Assets by Reportable Segment [Abstract]
Assets	30,897	25,112
Operating Segments [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	7,449	5,681
Cost of revenues	3,709	3,124
Gross profit	$ 3,740	$ 2,557
Gross profit %	50.20%	45.00%
Allocated expenses [Abstract]
Engineering and product development	$ 183	$ 173
Selling and marketing	849	601
Unallocated expenses	0	0
Total operating expenses	1,032	774
Income (loss) from operations	2,708	1,783
Interest expense	0	0
Interest income	0	0
Gain on debt extinguishment	0
Loss before income tax expense	2,708	1,783
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	7,449	5,681
Total Assets by Reportable Segment [Abstract]
Assets	2,662	3,052
Operating Segments [Member] \| Domestic [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	21,215	16,848
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	21,215	16,848
Operating Segments [Member] \| Domestic [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	1,982	956
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	1,982	956
Operating Segments [Member] \| Foreign [Member] \| Dermatology Recurring Procedures [Member]
Results of Operations from Business Segments [Abstract]
Revenues	1,313	561
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	1,313	561
Operating Segments [Member] \| Foreign [Member] \| Dermatology Procedures Equipment [Member]
Results of Operations from Business Segments [Abstract]
Revenues	5,467	4,725
Disaggregation of Revenue by Geographical Region [Abstract]
Revenues	5,467	4,725
Other Unallocated Assets [Member]
Total Assets by Reportable Segment [Abstract]
Assets	$ 13,034	$ 18,614

Subsequent Events (Details) - TheraClear Corporation [Member] - Subsequent Event [Member] $ in Millions	1 Months Ended
	Jan. 31, 2022 USD ($) shares
Subsequent Events [Abstract]
Upfront cash payment	$ 0.5
Number of shares issued in connection with asset acquisition (in shares) \| shares	358,367
Aggregate value of common stock issued in connection with asset acquisition	$ 0.5
Foreign [Member]
Subsequent Events [Abstract]
Percentage of gross profit for future royalty payments for subsequent period	25.00%
Subsequent period of gross profit for future royalty payments	4 years
Maximum [Member]
Subsequent Events [Abstract]
Future earnout payments	$ 3.0
Future milestone payments	1.0
Maximum [Member] \| Domestic [Member]
Subsequent Events [Abstract]
Future royalty payments	$ 20.0